Parallel
Parallel is the first tech-forward provider of learning assessments and treatment solutions for students with learning differences. The company specializes in virtual neurodevelopmental assessments and support services for conditions such as dyslexia, dysgraphia, dyscalculia, and executive dysfunction.
$61.25M
Latest Funding
Series A
Latest Funding Stage
2024-01-11
Funding Date
111
Employees
United States
Location
New York, New York
City & State
Sales-Ready Summary
Parallel Learning recently raised $61.25M in Series A funding and is actively hiring Speech Language Pathologists, signaling potential expansion in their services and a need for related tools and resources.
Key Contacts
Open Positions
View Careers PageHiring For
Similar Startups
Reddy
Reddy is an AI-powered platform that helps turn rookie hires into all-stars. Our talent hub allows for large enterprises to connect Recruiting, L&D and Operations in one home, with AI tools for each department that are tuned to your business' DNA. By optimizing talent pipelines, Reddy allows users to decrease turnover while increasingsales and support.
EG 427
EG 427 develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.
Reverb Therapeutics
Reverb Therapeutics uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokine, enabling cancer patients and the healthcare sector to redirect endogenous cytokines already in the body to cells of interest and treat cancer.
EnPlusOne Biosciences
EnPlusOne Biosciences offers enzymatic-based RNA synthesis to address systemic issues inherent to existing chemical synthesis methods and the expansion of RNA therapeutics has uncovered key issues including scaled production and access to innovative therapeutic modifications, enabling the manufacturing process to deliver therapeutic RNA at a commercial scale sustainably.